Alseres Pharmaceuticals, Inc. is the sponsor of clinical trials for an investigational molecular imaging agent, ALTROPANE®, that when used with SPECT imaging may help in the diagnosis of Parkinson's or Essential Tremor (POET). If doctors can better differentiate Parkinsonian tremors from non-Parkinsonian tremors, they can get a headstart in providing the proper treatment for patients. For more information, call 1.781.939.0799 or email us at trials@alseres.com. Trial information is also available on clinicaltrials.gov.
ALTROPANE scans visualize areas of the brain thought to be affected by PD.
Subjects for POET-2 Program AIM Trial can be referred by their physician or can contact a participating site directly.